Exploring Treatment Options for Psoriasis
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, June 12, 2016
Note: Credit Is No Longer Available
|April W. Armstrong, MD, MPH
Vice Chair of Clinical Research
Associate Professor of Dermatology
Director, Clinical Trials and Outcomes Research
Director, Psoriasis Program
Department of Dermatology
Colorado Health Outcomes Program
University of Colorado Denver, School of Medicine
|David G. Borenstein, MD, MACP, MACR
Clinical Professor of Medicine
Division of Rheumatology
The George Washington University Medical Center
Psoriasis is an inflammatory, autoimmune disorder with predominately joint and skin symptoms characterized by scaling and erythematous plaques that may be painful or severely pruritic, and may cause significant quality of life issues.
Psoriasis is severely undertreated or not treated at all. According to the National Psoriasis Foundation survey conducted from 2003 through 2011, there were significant numbers of patients who did not receive any treatment or received only topical agents even with moderate or severe psoriasis resulting in widespread treatment dissatisfaction.1 These results are in stark divergence from professional treatment guidelines that recommend treatment with topical agents for mild psoriasis and systemic, biologic, or combination treatment for moderate or severe psoriasis.2 Armstrong and colleagues concluded that education is necessary to ensure that patients have access to effective treatments.1
Dr. Armstrong joins Dr. Borenstein in this CME Outfitters Snack to discuss relevant treatment guidelines and recommendations for implementing treatment for patients with psoriasis.
- Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185. PMID: 23945732.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. PMID: 18423260.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Implement treatment according to treatment guidelines for mild and moderate-to-severe psoriasis.
At the end of this CE activity, participants should be able to:
- Implement treatment according to professional guidelines for more than 50% of my patients with psoriasis in the next three months.
Supported by educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Physicians, physician assistants, nurse practitioners, pharmacists, and other health care professionals with an interest in psoriasis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-15-020-H01-P (recorded programs)
Activity Type: knowledge-based
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Armstrong has disclosed that she has received research and grant support from Amgen Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. She serves as a consultant for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.
Dr. Borenstein has disclosed that he serves on the advisory board of AbbVie Inc.; Amgen Inc.; Iroko Pharmaceuticals, LLC; Pfizer Inc.; and is a consultant to Janssen Pharmaceuticals, Inc. He has received other financial or material support from the Board of Directors, Patient Access Network.
Erica Perilstein, MD (peer reviewer) has nothing to disclose.
Frances Daniel, MPH (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).